Literature DB >> 9870203

Benefits of normalizing plasma phenylalanine: impact on behaviour and health. A case report.

K Williams1.   

Abstract

An elderly man with mental retardation who had never received dietary treatment for his phenylketonuria was placed on a phenylalanine-restricted diet. Social skills and walking gait improved and a new interest in the objects in his environment developed spontaneously. A 2-year analysis of diet, blood plasma phenylalanine levels and behavioural state indicated that small differences in phenylalanine intake impacted his well-being. Of significant note, leg tremor and spasm that precipitated severe self-injury were only reversible when plasma blood phenylalanine concentrations were titrated to near normal ranges and daily phenylalanine intake was strictly controlled. This case may offer a potential explanation for some of the late treatment failures that have been reported and suggest new avenues to explore in the late treatment of PKU.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870203     DOI: 10.1023/a:1005482732411

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  15 in total

1.  Maternal phenylketonuria pregnancy outcome: a preliminary report of facial dysmorphology and major malformations.

Authors:  B Rouse; L Lockhart; R Matalon; C Azen; R Koch; W Hanley; H Levy; F dela Cruz; E Friedman
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  Dietary treatment of adult patients with phenylketonuria.

Authors:  L Hambraeus; G Holmgren; G Samuelson
Journal:  Nutr Metab       Date:  1971       Impact factor: 4.169

3.  Improvements in behaviour and physical manifestations in previously untreated adults with phenylketonuria using a phenylalanine-restricted diet: a national survey.

Authors:  S Yannicelli; A Ryan
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 4.  Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome.

Authors:  S E Waisbren; R R Schnell; H L Levy
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

5.  Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet.

Authors:  A MacDonald; G Rylance; S K Hall; D Asplin; I W Booth
Journal:  Arch Dis Child       Date:  1996-05       Impact factor: 3.791

6.  Impaired sensitivity to visual contrast in children treated early and continuously for phenylketonuria.

Authors:  A Diamond; C Herzberg
Journal:  Brain       Date:  1996-04       Impact factor: 13.501

7.  Neurological deterioration in adult phenylketonuria.

Authors:  D Villasana; I J Butler; J C Williams; S M Roongta
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

8.  Blocking effect of intraperitoneal injection of phenylalanine on high-threshold calcium currents in rat hippocampal neurones.

Authors:  A E Martynyuk; S Savina; G G Skibo
Journal:  Brain Res       Date:  1991-06-28       Impact factor: 3.252

9.  Agoraphobia in phenylketonuria.

Authors:  S E Waisbren; H L Levy
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

10.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

View more
  2 in total

1.  Characterization of tremor in phenylketonuric patients.

Authors:  Belén Pérez-Dueñas; Josep Valls-Solé; Emilio Fernández-Alvarez; Jaon Conill; Maria Antonio Vilaseca; Rafael Artuch; Jaume Campistol
Journal:  J Neurol       Date:  2005-07-05       Impact factor: 4.849

Review 2.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.